Bio-Gene Technology Ltd
Bio-Gene Technology Targets March 2027 APVMA Submission for Flavocide as Toxicology Studies Continue
Bio-Gene targets APVMA submission for Flavocide in March 2027 as toxicology studies progress, but faces ongoing cash burn and fundraising risk.
Bio-Gene Secures OMRI Approval for Qcide Organic Listing under USDA National Organic Program
Bio-Gene Technology (ASX: BGT) has received approval from the Organic Materials Review Institute in the US to list its Qcide natural insecticide as a Botanical Pesticide under the USDA National Organic Program.
Bio-Gene Reports Strong Flavocide Results Against Ticks to Leading US Lyme Disease Conference
Bio-Gene Technology (ASX: BGT) has released new data confirming that its lead compound Flavocide delivers strong activity against ticks responsible for spreading Lyme disease in the United States. Presented by Purdue University researchers at the International Conference on Lyme Borreliosis and Other Tick-Borne Diseases in Chicago, the findings showed that Flavocide achieved more than 90% […]
Bio-Gene awarded $3m in US grants to develop insecticides for military use
Bio-Gene Technology (ASX: BGT) has been awarded $3 million in grants by the US Department of Defense to develop insecticide products to protect its workforce from threats posed by disease-carrying species including mosquitoes and ticks. The grants have been provided under the government’s Deployed Warfighter Protection research program. The program aims to identify and test […]